(Received for publication May 20, 1993) WS1279, a new lipopeptide isolated from the fermentation broth of Streptomyces willmorei No. 1279, stimulated the proliferation of mousebone marrowcells in vitro and accelerated the recovery of granulocyte counts in bone marrow from leukopenia induced by mitomycin C (MMC)in mice. The glycerylcysteine moiety of WS1279is necessary and the lipid peptide structure is required for manifestation of full stimulating activity in vitro. WS1279 was the most effective on the proliferation of bone marrowcells amongthe tested immunostimulantsin vitro. However, the effect of WS1279 on restoration of reduced granulocyte counts in MMC-induced leukopenia in mice was less than that of FK-565, lipopolysaccharide, picibanil or forphenicinol. WS1279 augmentedhost resistance to infection with Staphylococcusaureus 47 in normal and immunosuppressed mice.
Bone marrow suppression is the most important side effect limiting the dose of cancer chemotherapy or radiotherapy1*. A major impediment to dose escalation is infection during the associated myelosuppression2)3). Therefore, drugs that prevent the infection or accelerate recovery from iatrogenic myelosuppression are clinically useful. palmitoyl-Cys-Asn-Ser-Gly-Gly-Ser-OH and was confirmed by synthesis6 '7) . In the present study we investigated the myelopoietic activity of WS1279in vitro and the ability to restore the number of granulocytes from leukopenia and to recover the host resistance to microbial infection in immunosuppressed mice by WS1279 in vivo.
Materials and Methods

Animals
Specific pathogen-free female BDFi mice were purchased from Charles River Japan. 2,3-bis(palmitoyloxy)propyl]-7V-palmitoyl-Cys-OH (2) was purchased from Boehringer Mannheim GmbH. Synthetic WS1279 and its synthetic intermediates,
and H-AsnSer-Gly-Gly-Ser-OH (6), were obtained as described previously7*.
Drugs
Mitomycin C (MMC) was purchased from Kyowa Hakko Kogyo Co., Ltd. FK-565 and forphenicinol were prepared in our laboratories. Lipopolysaccharide (LPS, Escherichia coli 055: B5), picibanil, muramyl dipeptide (MDP) and bestatin were obtained from Difco Laboratories, Chugai Pharmaceutical Co., Ltd., Sigma Chemical Co. and Nippon Kayaku Co., Ltd., respectively.
Preparation of MouseBone MarrowCells
Bone marrow cells of BDFXmice, 6~9 weeks of age, were prepared from their femurs. The bone marrow cells (3 x 106cells/ml) were suspended in Dulbecco's modified Eagle's medium(DMEM) containing 10% heat inactivated fetal bovine serum (FBS), lOOu/ml benzylpenicillin, 100//g/ml streptomycin, 5 x 10~5 m 2-mercaptoethanol and 2.5% L929 cell-conditioned medium (LCM).
Proliferation of Bone Marrow Cells Bone marrow cell suspension (25[A) and sample solution (50[A) in DMEM were mixed per well of 96-well flat-bottomed microtiter plates (Sumitomo Bakelite) and incubated at 37°C in a humidified atmosphere of 5%CO2in air for 4 days. The proliferation of bone marrow cells were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2^r-tetrazolium bromide (MTT) method8). The reduced MTT was dissolved in 0.04n HC1 with isopropanol, and then, absorbance was measured at 550 nm with reference at 660nmusing a microplate reader (MTP100,Corona Electric). Normal female BDFi mice, 6 weeks old, were intraperitoneally infected with 1.8 x 108 cells of S. aureus 47 suspended in 5% mucin (1/2MLD) on day 0. Synthetic WS1279 was suspended in 0.5% methylcellulose and intraperitoneally administrated daily for the three consecutive days (-3 to -1 day) before infection. Immunosuppressed BDFXmice produced by a single intraperitoneal treatment with 4.6mg/kg of MMCthree days prior to infection were infected intraperitoneally with 1.2 x 107cells of S. aureus 47 in 5% mucin suspension (1/2MLD). Synthetic WS1279suspended in 0.5% methylcellulose was intraperitoneally administrated 1 hour after MMCinjection and daily for the two consecutive days.
The mortality and the body weight of the survived mice were recorded on day 3 after infection.
Induction of CSF Synthetic WS1279 suspended in 0.5% methylcellulose was administrated subcutaneously into female BDFi mice (7 weeks old). Five hours after the administration of WS1279, the level of CSF in the serum was determined by measuring the proliferation of bone marrow cells as described above8). The serum was added at 10% concentration in the DMEM without 2.5% LCM.
Statistical Analysis Statistical analysis was carried out by Student's r-test.
Results
Myelopoietic Activity of WS1279 In Vitro Natural and synthetic WS1 279 were investigated for their ability to stimulate the proliferation of mouse bone marrowcells according to the method described in Materials and Methods. The mitogenic effects of natural and synthetic WS1279on bone marrow cells of BDFXmice can be seen from the dose response plots in Fig. 2 . The ED50 values (50% increase over control) of natural and synthetic WS1279 on the proliferation of bone marrow cells of BDFXmice were 0.33 //g/ml and 1.3 jjg/ml, respectively.
In order to determine more precisely the minimum structural requirements of WS1279(1) for myelopoietic activity in vitro, various synthetic fragments of WS1279were examined. As shown in (6) did not exhibit any myelopoietic activity.
Effect of WS1279on Restoration of Granulocytes in Bone Marrow
Weestablished the MMC-induced myelosuppressive modelin mice to estimate the usefulness in vivo of myelopoietic substances isolated in the screening program. It is knownthat MMC is one of the drugs useful for cancer chemotherapybut causes severe myelosuppression as a side effect1*. WhenBDF1mice were given with MMC intraperitoneally, the number of granulocytes in bone marrow decreased and reached a nadir on day 3 after injection, and then began to increase on day 4. On day 5, the granulocyte counts increased over that of non-treated control mice (data not shown). Weexamined the ability of WS1279to enhance the recovery of granulocyte counts in bone marrow in the MMC-inducedmouse leukopenia model.
Effects of natural and synthetic WS1279on the granulocyte counts in the MMC-inducedmouse leukopenia model are shown in Fig. 4 . Natural and synthetic WS1279were suspended in 0.5% methylcellulose. BDFXmice were administrated WS1279intraperitoneally once a day for 3 days after MMC treatment, and bone marrow cells from their femurs were harvested on day 3. The absolute number of granulocytes in bone marrow was measured by flow cytometry as described in materials and methods. Natural and synthetic WS1279increased the number of granulocytes dose-dependently. The ED50 values (50% restoration from MMC-treated control) of natural and synthetic WS1279 were 0.13mg/kg and 0.8 mg/kg, respectively. The restoration of granulocyte counts after administration of synthetic WS1279
(lOmg/kg) in MMC-treated mice is shown in Fig. 5 . Synthetic WS1279 augmented the decreased number of granulocytes to the normal level on day 3 after MMCtreatment. While in MMC-treated mice without WS1279, granulocyte counts reached a nadir on day 2 and did not change on day 3. Granulocytes were stimulated to proliferate, when WS1279was administrated alone. Prophylactic Effect of Synthetic WS1279on a Systemic Mouse Infection Model The prophylactic effect of synthetic WS1279on S. aureus 47 infection in normal mice and MMCinduced immunosuppressed mice is shown in Table 1 . WS1279enhanced the protective effect to S. aureus 47 infection at doses of l.lmg/kg to lOmg/kg in normal mice. Five out of 15 mice died within 3 days 
Induction of CSF
As it had been known that CSFs stimulated the proliferation of bone marrowcells10), we investigated the CSF-inducing activity of WS1279in the serum in BDF! mice by subcutaneous administration. As shown in Fig. 6 , the CSF level increased in 2hours after administration of WS1279(lO mg/kg), reached a maximumin 5 hours and kept plateau for 30 hours. WS1279induced CSF in mouse serum in a dose-dependent manner (1 to lOOmg/kg, Fig. 7 ).
Effects of Various Immunostimulants on Bone Marrow Proliferation Immunostimulants such as FK-56511*, LPS12), picibanil13), MDP14), bestatin15) and forphenicinol16) have been reported to have CSF-inducing activity. Additionally, bestatin17)18) and muroctasin (MDPLys) 19 ) have shown to have the hematopoietic effect in immunosuppressed animals. Weexaminedthe effects of WS1279and various immunostimulants on the proliferation of bone marrow cells in vitro and in vivo. The results are shown in Table 2 . Synthetic WS1279was the most effective on the proliferation of bone marrow cells. No proliferating activity of FK-565, picibanil and bestatin was observed in vitro. The ED50 values of MDP,LPS and forphenicinol could not be determined in vitro, because their efficacies were under 50%. On the other hand, FK-565, LPS, picibanil and forphenicinol were more effective than Gly-Ser-OH structure. Natural and synthetic WS1279 stimulated the proliferation of mouse bone marrow cells in vitro. WhenWS1279was administrated intraperitoneally in MMC-treated mice, the reduced number of granulocytes in bone marrow was restored. Though the synthetic WS1279was identical with the natural product on thin layer chromatography and HPLC7), their activities in vitro as well as in vivo in the proliferation of bone marrow cells were rather discrepant. These differences in activity between the synthetic sample and the natural product maybe due to the fact that the synthetic sample was a diastereomeric mixture. Kurimura et al.20) Asn-Ser-Gly-Gly-Ser-OH (6) did not exhibit any stimulating activity (Fig. 3) . These results suggest that a lipid peptide structure with a certain chain length is required for manifestation of full stimulating activity. We tried to determined whether the addition of 2.5% LCMwould increase the proliferating activity of WS1279. WS1279stimulated the growth of bone marrow cells dose-dependently in DMEM without LCM.The data show that 2.5% of LCMhas an incremental effect on the proliferation of bone marrow cells in vitro (Fig. 8) .
WS1279increased the number of granulocytes in MMC-inducedleukopenic mice. This effect may be due to the following mechanisms of WS1279; 1) an effect mediated through CSF induction, or 2) a direct effect on granulocytes. Recently we reported that FK-565accelerated recovery of the number of granulocytes in MMC-treated mice and this result may be mediated through CSF induction1 1>21). WS1279 induced CSF in mouse serum (Figs. 6 and 7) , but the CSF level was very low as compared with that induced by FK-565 (data not shown). Their CSF-inducing ability may be related to their granulopoietic activity in vivo. It remains a problem for the future to determine the mechanismof granulopoiesis stimulated byWS1279.
Bestatin was reported to restore leukocyte counts in myelosuppressed mice17'18), however, bestatin NOV. 1993 did not stimulate granulopoiesis in MMC-induced leukopenic mice (Table 2 ). This discrepancy may be due to the difference in experimental animal models.
In addition, WS1279enhanced host resistance to infection with Staphylococcus aureus 47 in normal and immunosuppressed mice (Table 1) . These results suggest that prophylactic effect of WS1279on the infection may be induced by an increase in granulocyte numbers.
